Edition:
India

Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

39.22USD
16 Aug 2019
Change (% chg)

$1.73 (+4.61%)
Prev Close
$37.49
Open
$37.87
Day's High
$39.33
Day's Low
$37.73
Volume
136,239
Avg. Vol
198,331
52-wk High
$67.86
52-wk Low
$29.17

About

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being... (more)

Overall

Beta: --
Market Cap(Mil.): $2,330.31
Shares Outstanding(Mil.): 51.78
Dividend: --
Yield (%): --

Financials

Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod

Biohaven Pharmaceutical Holding Co Ltd said on Friday the U.S. health regulator failed to approve its treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease, sending its shares down nearly 6% in extended trading.

20 Jul 2019

Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod

Biohaven Pharmaceutical Holding Co Ltd said on Friday the U.S. health regulator failed to approve its treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease, sending its shares down nearly 6% in extended trading.

20 Jul 2019

Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod

July 19 Biohaven Pharmaceutical Holding Co Ltd said on Friday the U.S. health regulator failed to approve its treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease, sending its shares down nearly 6% in extended trading.

20 Jul 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates